TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32828927

Group type: EXPERIMENTAL
Intervention: Virtual high-intensity intermittent aerobic exercise (vHIE) in first-person perspective (1PP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Virtual high-intensity intermittent aerobic exercise (vHIE) in third-person perspective (3PP)
Number of subjects: 45
Study: 35237336

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 90

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 90
Study: 34049672

Group type: EXPERIMENTAL
Intervention: 1 to 3 months of dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy
Number of subjects: 18046

Group type: COMPARATOR
Intervention: 12 months of dual antiplatelet therapy (DAPT)
Number of subjects: 18046
Study: 32122921

Group type: EXPERIMENTAL
Intervention: High dose cytarabine
Number of subjects: 348

Group type: COMPARATOR
Intervention: Standard dose cytarabine
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Variant genotype rs17202778 C/C
Number of subjects: 348
Study: 33112481

Group type: EXPERIMENTAL
Intervention: Faecal REG1B concentration
Number of subjects: 694
Study: 36208303

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention (MB-SI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mindfulness-Based Intervention (MB-SI) and Treatment as Usual (TAU)
Number of subjects: 20
Study: 34044838

Group type: EXPERIMENTAL
Intervention: Hypnosis group (standardized hypnotic message)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard group (no intervention)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Music group (relaxing music)
Number of subjects: 69
Study: 32167593

Group type: EXPERIMENTAL
Intervention: Standard therapy for former smokers
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Standard therapy for current smokers
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Standard therapy for former smokers with ≤20 pack-years
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Standard therapy for all patients
Number of subjects: 330
Study: 35697146

Group type: EXPERIMENTAL
Intervention: bamlanivimab
Number of subjects: 1935

Group type: EXPERIMENTAL
Intervention: bamlanivimab-etesevimab
Number of subjects: 1935

Group type: COMPARATOR
Intervention: casirivimab-imdevimab
Number of subjects: 1935
Study: 34492446

Group type: EXPERIMENTAL
Intervention: 7 days of antibiotic therapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 14 days of antibiotic therapy
Number of subjects: 45
Study: 34059425

Group type: EXPERIMENTAL
Intervention: Individualized intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 32
Study: 32482611

Group type: EXPERIMENTAL
Intervention: 5% aluminium zirconium tetrachlorohydrate antiperspirant solution (AZCH)
Number of subjects: 14
Study: 32197030

Group type: EXPERIMENTAL
Intervention: Subarachnoid anesthesia combined with propofol TCI (group T)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: General anesthesia (GA) (group G)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Combined spinal-epidural anesthesia (CSEA) (group C)
Number of subjects: 240
Study: 37183134

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy in stoma patients
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard care in stoma patients
Number of subjects: 69
Study: 33919059

Group type: EXPERIMENTAL
Intervention: Mind&Life intervention (ACT and mindfulness-based intervention plus TAU)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 110
Study: 32194443

Group type: EXPERIMENTAL
Intervention: Cariprazine (1.5-6 mg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 66
Study: 35050952

Group type: EXPERIMENTAL
Intervention: Alternate-day fasting (ADF)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 16/8 time-restricted fasting (16/8 TRF)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study: 33252552

Group type: EXPERIMENTAL
Intervention: Large head THA (Group A)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Dual mobility cup designs (Group B)
Number of subjects: 165
Study: 33142503

Group type: EXPERIMENTAL
Intervention: L-DNJ (0.05 mg/g)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: M-DNJ (0.1 mg/g)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: H-DNJ (0.15 mg/g)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control (ordinary diet without DNJ)
Number of subjects: 128
Study: 33935111

Group type: EXPERIMENTAL
Intervention: Cerebrolysin plus routine intervention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine intervention program alone
Number of subjects: 0
Study: 36433591

Group type: EXPERIMENTAL
Intervention: Oxytocin (5 IU intravenously)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Carbetocin (100 μg intramuscularly)
Number of subjects: 64
Study: 33225442

Group type: EXPERIMENTAL
Intervention: Robotic assisted gait training (RAGT) combined with locomotor training (LT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Locomotor training (LT) alone
Number of subjects: 40
Study: 35245895

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: KT-placebo
Number of subjects: 51

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 51

Group type: COMPARATOR
Intervention: All groups (KT, KT-placebo, No-treatment control)
Number of subjects: 51
Study: 32371705

Group type: EXPERIMENTAL
Intervention: 1.73% lidocaine carbonate (Group D)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Air (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Double distilled water (Group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 2% lidocaine hydrochloride (Group C)
Number of subjects: 80
Study: 34928693

Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy
Number of subjects: 156

Group type: COMPARATOR
Intervention: General psychiatric management
Number of subjects: 156
Study: 32244028

Group type: EXPERIMENTAL
Intervention: Dengzhan Shengmai (DZSM) capsules
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 35613725

Group type: EXPERIMENTAL
Intervention: Eldecalcitol 0.75 μg per day (n=630)
Number of subjects: 1256

Group type: COMPARATOR
Intervention: Placebo (n=626)
Number of subjects: 1256
Study: 34988058

Group type: EXPERIMENTAL
Intervention: Digital intervention for medication adherence
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Tailored intervention content and reporting on medication taking
Number of subjects: 57
Study: 32842644

Group type: EXPERIMENTAL
Intervention: Narrow-pyramid resistance training (NPR), 3 sets of 12/10/8 repetitions, 3x/week for 8 weeks
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Wide-pyramid resistance training (WPR), 3 sets of 15/10/5 repetitions, 3x/week for 8 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Non-exercise control (CON)
Number of subjects: 59
Study: 34841615

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 515

Group type: COMPARATOR
Intervention: Control (no spironolactone)
Number of subjects: 515
Study: 34735643

Group type: EXPERIMENTAL
Intervention: Virtual reality intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hospital routine care (control)
Number of subjects: 60
Study: 35597311

Group type: EXPERIMENTAL
Intervention: Laryngeal tube (LT)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Endotracheal intubation (ETI)
Number of subjects: 1000
Study: 33112184

Group type: EXPERIMENTAL
Intervention: KdD70 (once-weekly carfilzomib 70 mg/m2, dexamethasone, and daratumumab)
Number of subjects: 0

Group type: COMPARATOR
Intervention: KdD56 (twice-weekly carfilzomib 56 mg/m2, dexamethasone, and daratumumab)
Number of subjects: 0
Study: 33278330

Group type: COMPARATOR
Intervention: Single ascending dose (SAD) of vixotrigine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Multiple ascending dose (MAD) of vixotrigine (450 mg twice daily)
Number of subjects: 81
Study: 32596729

Group type: EXPERIMENTAL
Intervention: Potassium supplement (90 mmol/day)
Number of subjects: 25
Study: 36068547

Group type: EXPERIMENTAL
Intervention: Bayesian platform trial design with beta-binomial model for binary outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response-adaptive randomization (RAR) schemes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hierarchical modeling of subgroups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjustment for potential drift over time
Number of subjects: 0
Study: 34160347

Group type: EXPERIMENTAL
Intervention: TetraStim (four consecutive minimal COS)
Number of subjects: 128
Study: 33066857

Group type: EXPERIMENTAL
Intervention: Electrical moxibustion (EM)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Traditional indirect moxibustion (TIM)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 138
Study: 34173940

Group type: EXPERIMENTAL
Intervention: Calcifediol
Number of subjects: 284

Group type: COMPARATOR
Intervention: Control (no additional therapy)
Number of subjects: 284
Study: 34684368

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg·kg−1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resistance training intervention
Number of subjects: 30
Study: 32516494

Group type: EXPERIMENTAL
Intervention: Comparison chart format
Number of subjects: 301

Group type: COMPARATOR
Intervention: Sequential text descriptions
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Both formats
Number of subjects: 301
Study: 34246515

Group type: EXPERIMENTAL
Intervention: BCT + IBT
Number of subjects: 75

Group type: COMPARATOR
Intervention: IBT
Number of subjects: 75
Study: 32473678

Group type: EXPERIMENTAL
Intervention: Acalabrutinib with obinutuzumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acalabrutinib without obinutuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorambucil and obinutuzumab
Number of subjects: 0
Study: 2012036615

Group type: EXPERIMENTAL
Intervention: Olmesartan, 40 mg daily
Number of subjects: 4447

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4447
Study: 35630559

Group type: EXPERIMENTAL
Intervention: 1 mmol salicylic acid with full irrigation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 mmol salicylic acid in dryland
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 mmol salicylic acid with 50% irrigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 mmol salicylic acid with non-irrigation
Number of subjects: 0
Study: 32903125

Group type: EXPERIMENTAL
Intervention: Trapeziectomy alone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Trapeziectomy with LRTI
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 33436851

Group type: EXPERIMENTAL
Intervention: Domain randomization strategy applied to deep learning models for bird detection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional manual observations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-term bird surveys using intensive monitoring
Number of subjects: 0
Study: 34035100

Group type: EXPERIMENTAL
Intervention: Butylphthalide (NBP)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study: 32063035

Group type: EXPERIMENTAL
Intervention: Continuous ultrasound applied in the first and second months (Group III)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound applied in the first month (Group II)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Continuous ultrasound applied in the first month (Group I)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound applied in the first and second months (Group IV)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Exercise sessions only for eight weeks (Group V)
Number of subjects: 100
Study: 35712941

Group type: EXPERIMENTAL
Intervention: Combined group (acupuncture at sphenopalatine ganglion + conventional acupuncture)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Acupuncture group (conventional acupuncture)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Sphenopalatine ganglion group
Number of subjects: 180
Study: 33639508

Group type: EXPERIMENTAL
Intervention: LC@I‐PANi nanoparticles
Number of subjects: 0
Study: 32758135

Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral psychotherapy tailored to the specific needs of the population, provided by residential psychotherapists as part of the regular healthcare service.
Number of subjects: 130

Group type: COMPARATOR
Intervention: Individual psychosocial telephone counselling and a self-help guide (active control group).
Number of subjects: 130
Study: 36378768

Group type: EXPERIMENTAL
Intervention: Intervention group (Strong Hearts, Healthy Communities-2.0 program)
Number of subjects: 182
Study: 32399201

Group type: EXPERIMENTAL
Intervention: Personalised text message
Number of subjects: 403

Group type: COMPARATOR
Intervention: Standard text message
Number of subjects: 403
Study: 32639293

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin, n = 6
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo, n = 7
Number of subjects: 13
Study: 35218248

Group type: EXPERIMENTAL
Intervention: Xenograft plus a collagen membrane
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Allograft plus a collagen membrane
Number of subjects: 24
Study: 33405291

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (triggered by hemoglobin ≤8 g/dL)
Number of subjects: 630

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (triggered by hemoglobin ≤10 g/dL)
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 630

Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 630
Study: 35556167

Group type: EXPERIMENTAL
Intervention: Subcuticular suture with cyanoacrylate skin adhesive
Number of subjects: 834

Group type: COMPARATOR
Intervention: Stapled skin closure (historical control group)
Number of subjects: 834
Study: 34659110

Group type: EXPERIMENTAL
Intervention: Dulening metformin SR tablets (n=446)
Number of subjects: 886

Group type: COMPARATOR
Intervention: Glucophage metformin tablets (n=440)
Number of subjects: 886
Study: 34708917

Group type: EXPERIMENTAL
Intervention: Difelikefalin (5 and 15 mcg/kg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Pentazocine (0.5 mg/kg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 35852035

Group type: EXPERIMENTAL
Intervention: Cooled dialysate (35.5°C)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Routine dialysate (36.5°C)
Number of subjects: 45
Study: 33211251

Group type: EXPERIMENTAL
Intervention: qCON (Conox) during desflurane anesthesia
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: PSI (Sedline) during desflurane anesthesia
Number of subjects: 22

Group type: COMPARATOR
Intervention: qCON and PSI during sevoflurane-propofol anesthesia (Control)
Number of subjects: 22
Study: 34936072

Group type: EXPERIMENTAL
Intervention: trans‐SAP PETLD
Number of subjects: 98

Group type: COMPARATOR
Intervention: conventional PETLD
Number of subjects: 98
Study: 33109138

Group type: EXPERIMENTAL
Intervention: Information only group
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Information plus home delivery group
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 720
Study: 35135037

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 33388858

Group type: EXPERIMENTAL
Intervention: Curcuminoids 500 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Curcuminoids 1000 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Curcuminoids (both dosages)
Number of subjects: 0
Study: 34415561

Group type: EXPERIMENTAL
Intervention: Single oral dose of 25 mg Omecamtiv mecarbil (OM)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Single oral dose of 50 mg Omecamtiv mecarbil (OM)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Multiple oral doses of 25 mg Omecamtiv mecarbil (OM)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Multiple oral doses of 37.5 mg or 50 mg Omecamtiv mecarbil (OM)
Number of subjects: 86
Study: 32605806

Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg every 2 weeks
Number of subjects: 186
Study: 35065057

Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy (240 mg every 2 weeks for up to three doses before surgery, then 480 mg every 4 weeks for 2 years)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nivolumab plus ipilimumab (240 mg nivolumab every 2 weeks plus 1 mg/kg ipilimumab concurrently with the first preoperative dose, then 480 mg nivolumab every 4 weeks for 2 years plus 1 mg/kg ipilimumab every 6 weeks for up to four cycles)
Number of subjects: 30
Study: 35473780

Group type: EXPERIMENTAL
Intervention: Interleukin-1 blockade (IL-1 blockade)
Number of subjects: 0
Study: 32970970

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation–assisted cycling (FESC) 4x/week for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Passive cycling (PC) 4x/week for 12 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation–assisted cycling (FESC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Passive cycling (PC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation–assisted cycling (FESC) and Passive cycling (PC)
Number of subjects: 24
Study: 33491205

Group type: EXPERIMENTAL
Intervention: Reinforcer delivery with 0% error
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reinforcer delivery with 5% error
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reinforcer delivery with 10% error
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reinforcer delivery with 15% error
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reinforcer delivery with 20% error
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reinforcer delivery with 25% error
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reinforcer delivery with 50% error
Number of subjects: 0
Study: 32827517

Group type: EXPERIMENTAL
Intervention: 1 mg ropinirole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34521264

Group type: EXPERIMENTAL
Intervention: 100,000 IUs of ergocalciferol monthly after bariatric surgery
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard level vitamin D supplement after bariatric surgery
Number of subjects: 32
Study: 32433198

Group type: EXPERIMENTAL
Intervention: Experimental cohort (223 patients) using the PRoFiT-NU Score for predicting functional outcomes.
Number of subjects: 328

Group type: COMPARATOR
Intervention: Validation cohort (105 patients) using the PRoFiT-NU Score for predicting functional outcomes.
Number of subjects: 328
Study: 34192426

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine (5-μg doses, 2 doses administered 21 days apart)
Number of subjects: 15187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15187

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine
Number of subjects: 15187

Group type: COMPARATOR
Intervention: NVX-CoV2373 vaccine and placebo
Number of subjects: 15187
Study: 32919280

Group type: EXPERIMENTAL
Intervention: CER-001 (8 mg/kg, intravenous infusions, 9 weekly infusions followed by infusions every two weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 34525100

Group type: EXPERIMENTAL
Intervention: Automated encouragement messages via e-mail and SMS before exams
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no encouragement messages)
Number of subjects: 0
Study: 32414130

Group type: EXPERIMENTAL
Intervention: Vitamin D levels < 30 ng/mL in AS patients
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Vitamin D levels < 20 ng/mL in AS patients
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Vitamin D levels < 10 ng/mL in AS patients
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Vitamin D levels < 30 ng/mL in male AS patients
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Vitamin D levels < 20 ng/mL in male AS patients
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Vitamin D levels < 10 ng/mL in male AS patients
Number of subjects: 919

Group type: COMPARATOR
Intervention: Inadequate levels of vitamin D among controls
Number of subjects: 919
Study: 32374239

Group type: EXPERIMENTAL
Intervention: Local TXA
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Systemic+short infusion TXA
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Systemic+long infusion TXA
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Systemic+oral TXA
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control
Number of subjects: 168
Study: 34582653

Group type: EXPERIMENTAL
Intervention: Lisinopril and Bisoprolol
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 74
Study: 32312606

Group type: EXPERIMENTAL
Intervention: Classification-specific treatment (exercise to control or prevent lumbopelvic motion during lower-extremity movement)
Number of subjects: 39

Group type: COMPARATOR
Intervention: General exercises and education about LBP (control group)
Number of subjects: 39
Study: 35894088

Group type: EXPERIMENTAL
Intervention: Home-based walking exercise inducing ischemic leg symptoms
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Home-based walking exercise without ischemic leg symptoms
Number of subjects: 264

Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 264
Study: 34018987

Group type: EXPERIMENTAL
Intervention: Methylated spirit
Number of subjects: 323

Group type: COMPARATOR
Intervention: Chlorhexidine gel
Number of subjects: 323
Study: 35997992

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 54

Group type: COMPARATOR
Intervention: General Physical Education (PE)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Passive Controls
Number of subjects: 54
Study: 34864925

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQ) 120/960mg
Number of subjects: 748

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP) 1500/75mg
Number of subjects: 748